source
- Skyhawk Therapeutics reports symptom improvement for Huntington's disease in Phase 1/2 extension studySkyhawk Therapeutics announced that its RNA-splicing candidate SKY-0515 showed a measurable improvement in symptoms for patients with Huntington's disease during an extension of its Phase 1/2 trial…
- Yale and Harvard faculty question benefits of FDA's 'America First' user fee provisionsYale and Harvard medical school faculty have voiced concerns about the latest FDA user fee agreement, which includes a set of "America First" provisions. The provisions are designed to prioritize…